External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Angiogenesis 2025
Roche and Genentech at

Angiogenesis 2025

February 08 - February 08
Virtual
umiamihealth.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Feb 9 / Roche and Genentech
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
This presentation reports findings from the RHONE-X extension trial, which evaluated the long-term safety and efficacy of faricimab▼ in patients with DME who completed either of the 2-year randomized phase 3 clinical trials (YOSEMITE/RHINE). This is the largest DME extension study to date with over 1400 patients enrolled. We also present a case study of a patient who followed for 4 years and was treated with aflibercept in YOSEMITE and switched to faricimab▼ in RHONE-X.
Ophthalmology Diabetic Macular Edema ANGIOGENESIS-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 9 / Roche and Genentech
First Time Analysis of Fellow Eyes with DME in the Pagoda Port Delivery System Study
In this post-hoc analysis of the Pagoda study, patients randomized to the PDS arm and having bilateral DME are evaluated. PDS Q24W in the study eye demonstrates greater CST and DRSS control, similar vision and safety outcomes with aVEGF IVT treatment in the fellow eye through week 112, with reduced treatment burden.
Ophthalmology Diabetic Macular Edema ANGIOGENESIS-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 9 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries/regions. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.
Ophthalmology Age Related Macular Degeneration ANGIOGENESIS-2025
08:35 PM
Duration 8mins Virtual
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G
Ophthalmology | Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:45 PM
Duration 8mins Virtual
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
John A Wells III
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:55 PM
Duration 8mins Virtual
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Veeral Sheth
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:55 PM
Duration 8mins Virtual
First Time Analysis of Fellow Eyes with DME in the Pagoda Port Delivery System Study
Eichenbaum D, Graff J, Hsieh Y, Hsu, J, Udaondo P, Wirthlin R, Blotner S, Gune S, Jones M, Santhanakrishan A, Schimpl A, Heinrich D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.